Acute infantile liver failure due to synthesis defect of mtDNA-encoded proteins
MONDO:0013111Acute infantile liver failure due to mtDNA-encoded proteins synthesis defect is a very rare mitochondrial respiratory chain deficiency described in fewer than 10 infants, primarily of middle Eastern descent, and characterized clinically by transient but life-threatening liver failure with elevated liver enzymes, jaundice, vomiting, coagulopathy, hyperbilirubinemia, and lactic acidemia.
Also known as: acute infantile liver failure, LFIT, TRMU infantile liver failure, acute infantile liver failure due to synthesis defect of mitochondrial DNA-encoded proteins, acute infantile liver failure due to synthesis defect of mtDNA-encoded proteins, infantile liver failure caused by mutation in TRMU, liver failure, infantile, transient, liver failure, transient infantile
22 clinical trials for this condition and its sub-types, 0 tagged with Acute infantile liver failure due to synthesis defect of mtDNA-encoded proteins itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug shows promise for rare energy disorder
Disease control CompletedThis study tested a new drug called OMT-28 in 28 people with primary mitochondrial disease, a condition that affects how cells produce energy. Participants took the drug once daily for 6 months, and researchers measured safety, blood markers of inflammation, and symptoms like fat…
Phase 2 • Sponsor: Omeicos Therapeutics GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Long-Term safety of mitochondrial drug confirmed in 101 patients
Disease control CompletedThis study looked at the safety of vatiquinone in 101 people with inherited mitochondrial disease who had already taken the drug in a previous study or treatment plan. The goal was to track any side effects until the drug became commercially available or the program ended. Partic…
Phase 3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Liver function may change how mavorixafor works in the body
Knowledge-focused CompletedThis study investigates how a single dose of mavorixafor is processed in people with mild to moderate liver impairment compared to healthy volunteers with normal liver function. Researchers will measure drug levels in the blood and monitor safety and tolerability. The goal is to …
Phase 1 • Sponsor: X4 Pharmaceuticals • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
New drug tested in people with liver disease
Knowledge-focused CompletedThis study looked at how the body handles a drug called BI 1584862 in people with different levels of liver function. 43 adults with mild, moderate, or severe liver problems, plus a group with healthy livers, took a single dose of the drug. Researchers measured drug levels in the…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Liver Function's impact on experimental brain drug tested
Knowledge-focused CompletedThis study looked at how the experimental drug iclepertin (BI 425809) is processed in people with and without liver problems. 29 adults aged 18-79 took a single dose of the drug. Researchers measured drug levels in the blood and monitored safety to see if liver impairment changes…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Liver transplant study may unlock clues to artery hardening
Knowledge-focused CompletedThis pilot study looked at 38 liver transplant patients to see if liver failure lowers blood levels of pyrophosphate, a natural substance that prevents calcium buildup in tissues. Researchers measured pyrophosphate before and after transplant and checked liver tissue for a relate…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Liver function may change how this drug works
Knowledge-focused CompletedThis study looks at how the drug BI 1015550 is absorbed and processed in the blood of people with mild or moderate liver problems compared to those with healthy livers. About 28 adults took a single dose and had blood samples taken over several days. The goal is to understand if …
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Liver function may change how cancer drug imlunestrant works
Knowledge-focused CompletedThis completed Phase 1 study looked at how imlunestrant, an oral drug, enters the bloodstream and leaves the body in women with and without liver impairment. 27 female participants took a single dose, and researchers measured drug levels over time. The goal is to understand if li…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC